GlassScriptPhysician profile
Daniel H Dunbar
NPI 1114106747
$5,326.21
in general payments reported to CMS, 2019-2025
47 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $122 · 2022: $14.66 · 2023: $1,447 · 2024: $1,561 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,505.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $708.40 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $481.73 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $445.59 | 2019-2025 | |
| Abbott Laboratories | $410.28 | 2019-2025 | Freestyle Libre 3, Octrode |
| Novo Nordisk INC | $364.09 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $272.96 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $270.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $228.21 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $184.94 | 2023-2025 | |
| Amgen INC. | $159.10 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Stryker Corporation | $137.44 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Sanofi-Aventis U.S. LLC | $134.98 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $111.55 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.61 | 2023-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $86.83 | 2025 | Rexulti |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $82.55 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $82.41 | 2023-2024 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $78.73 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $78.39 | 2023 | |
| Tris Pharma INC | $66.92 | 2023-2024 | Dyanavel Xr |
| Phathom Pharmaceuticals, INC. | $55.97 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.19 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $50.14 | 2023-2025 | Rexulti |
| Halozyme INC | $49.50 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.80 | 2019 | |
| Dynavax Technologies Corporation | $39.40 | 2024-2025 | Heplisav-B |
| Daiichi Sankyo INC. | $36.68 | 2023-2025 | Injectafer |
| Antares Pharma, INC. | $34.31 | 2024 | Xyosted |
| Neos Therapeutics, LP | $33.56 | 2023 | Adzenys Xr-Odt |
| Genentech USA, INC. | $32.41 | 2019 | |
| Dexcom, INC. | $30.80 | 2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $30.73 | 2023-2025 | Contrave |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.45 | 2024-2025 | Caplyta |
| Adlon Therapeutics L.P. | $30.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.17 | 2023 | Xarelto |
| Hikma Pharmaceuticals USA | $28.07 | 2020-2024 | Ryaltris |
| Actelion Pharmaceuticals US, INC. | $27.90 | 2024 | Uptravi, Opsumit |
| Alexion Pharmaceuticals, INC. | $25.82 | 2025 | Strensiq |
| Axsome Therapeutics, INC. | $25.41 | 2025 | Symbravo |
| Cvrx, INC. | $25.16 | 2024 | Barostim Neo System |
| Inari Medical, INC. | $24.75 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Noven Therapeutics, LLC | $20.90 | 2024 | Xelstrym |
| Edwards Lifesciences Corporation | $20.64 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Acadia Pharmaceuticals INC | $19.14 | 2025 | Nuplazid |
| Irhythm Technologies, INC. | $18.90 | 2020 | |
| Ironshore Pharmaceuticals INC. | $16.00 | 2019 | |
| Tolmar, INC. | $14.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dunbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.